Dr Diana Brixner headshot

Diana I. Brixner, RPh, PhD, FAMCP

Academic Information

Departments President of International Society for Pharmacoeconomics and Outcomes Research (ISPOR) - College of Pharmacy , Professor - Pharmacotherapy , Member of Pharmacotherapy Outcomes Research Center - Pharmacotherapy , Past President Academy of Managed Care Pharmacy - Pharmacotherapy , Associate Member, HCI Cancer Control and Population Sciences Research Program - Huntsman Cancer Institute , Adjunct Professor, Department Pediatrics Population Health Science - Population Health Sciences

Academic Office Information

Diana.Brixner@utah.edu

--

Lab

Research Interests

  • Design, conduct, and communication of pharmacoeconomic and outcomes research studies

Dr. Diana Brixner is currently a Professor in the Department of Pharmacotherapy and is a Founder of the Pharmacotherapy Outcomes Research Center at the University of Utah in Salt Lake City, Utah. She is a member of the Huntsman Cancer Institute Cancer Control and Population Sciences and the Center for Genomic Medicine. Prior to her academic appointment in 2002 she worked both in the biotech (NeoRx) and pharmaceutical (SmithKline Beechman, Novartis) Industry focused on value assessment of their technologies in the early years of the field. Dr. Brixner was a past President for both the Academy of Managed Care Pharmacy (AMCP) and International Society of Pharmacoeconomics and Outcomes Research (ISPOR). She was recently a one-year Scholar-in-Residence for the Academy of Managed Care Pharmacy. She is also a member of the board of the International Market Access Society.

COURSES TAUGHT

  • PCTH 7123  - Pharmacy Management
  • PCTH 7538  - Outcomes Research/Pharmacoeconomics Clerkship
  • PCTH 5114  - U.S. Health Care Policy
  • PHARM 7552 - Managed Care Elective
  • MDCRC 6150  - Foundations in Personalized Health Care
  • PCTH 7115  - Multinational Health Care Policy

SERVICE

Department

  • Chair of Pharmacotherapy, 2002-2015

College

  • Member, College Research Strategy Committee 2020-2021

AWARDS AND HONORS

  • 2020 Best Poster Award, AMCP
  • 2020 Faculty of the Year, University of Utah
  • 2019 Teacher of the Year (P3), University of Utah
  • 2018 Top 10 Semi-Finalist, American Dream Ideas Challenge, University of Utah
  • 2018 Nominated Teach of the Yeah (P3 and P4)
  • 2014 Fellow of the Academy of Managed Care Pharmacy
  • 2013 Distinguished Alumnus Award, University of Rhode Island College of Pharmacy
  • 2011 Academy of Managed Care Pharmacy Board of Directors Service Award
  • 2009 International Society for Pharmacoeconomics and Outcome Research Presidential Service Award
  • 2007 National Community Pharmacists Association Top Ten Business Plan Award Student Mentor
  • 2007 American Association of Colleges of Pharmacy Walmart Scholarship Award Mentorship
  • 2006 American Foundation of Pharmaceutical Education (AFPE) Gateway to Research Scholarship Award Mentorship
  • 2006 Merck Leadership Service Award, Utah Pharmacists Association
  • 2003 Journal of Managed Care Pharmacy Award for Excellence Judging Panel
  • 2001 Distinguished Alumnus Award, University of Utah College of Pharmacy
  • 1999 Organizational Contributor Award, International Society of Pharmacoeconomics and Outcomes Research
  • 1998 Novartis Pioneer Award

RELATED LINKS

FAR Webpage

Pharmacotherapy Outcomes Research Center (PORC)

College of Pharmacy

Education History

Certification University of Health Science
 Introduction to Health Technology Assessment Certificate
Certification University of Health Sciences
 Clinical Epidemiology Certificate
Certification University of Health Sciences
 Modeling Approaches for Health Technology Assessment Certificate
Pharm D University of Utah
 Doctor of Philosophy in Medicinal Chemistry
Undergraduate University of Rhode Island
 Bachelor of Science

Selected Publications

Journal Article

  1. Joish VN, Donaldson G, Stockdale W, Oderda GM, Crawley J, Sasane R, Joshua-Gotlib S, Brixner DI. The economic impact of GERD and PUD: examination of direct and indirect costs using a large integrated employer claims database. Curr Med Res Opin. 2005 Apr;21(4):535-44. doi: 10.1185/030079905X38240. PMID: 15899102

  2. Asche CV, Brixner DI, Oderda GM. Has the cost-effectiveness of Xolair (omalizumab) been underestimated? J Allergy Clin Immunol. 2005 May;115(5):1095; author reply 1095-6. doi: 10.1016/j.jaci.2004.12.1136. PMID: 15867875

  3. Gunter MJ, Brixner D, von Worley A, Carter S, Gregory C. Impact of a seizure disorder disease management program on patient-reported quality of life. Dis Manag. 2004 Winter;7(4):333-47. doi: 10.1089/dis.2004.7.333. PMID: 15671790

    More Selected Publications

Clinical Trials